JAB-X1800 / Jacobio Pharma - LARVOL DELTA

JAB-X1800: A potent immunostimulatory antibody-drug conjugate (iADC) targeting CD73 (AACR 2023) - "The CD73-targeted STING agonist iADC JAB-X1800 demonstrated high stability in plasma, robust activity, and good tolerability in animal models, supporting clinical development of JAB-X1800 alone and in combination with anti-PD-1 for patients with CD73-expressing tumors."

IO biomarker • Oncology • IFNB1 • NT5E

Jacobio Pharma to Present Data of Three Preclinical Studies at the 2023 AACR Annual Meeting (PRNewswire) - "Jacobin Pharma...announced that the company will present the results of three preclinical studies of KRASmulti inhibitor JAB-23425, CD73-STING iADC JAB-X1800, and Aurora kinase A inhibitor JAB-2485 in form of the abstract during the American Association for Cancer Research (AACR) Annual Meeting 2023 (the 'AACR 2023') from April 14 to 19, 2023....JAB-23425 has significant antitumor effect on cancer models with multiple KRAS mutations (such as G12D, G12V, and G13D) and amplification of wild type KRAS, and has no inhibitory effect on KRAS-independent cells."

Preclinical • Oncology • Solid Tumor

Jacobio Pharma Announces 2022 Interim Results (PRNewswire) - "Jacobio is currently developing HER2 STING iADC JAB-BX400 and CD73-STING iADC JAB-X1800. IND applications for these two programs are expected to be submitted in 2024."

IND • Oncology